A Second View: Investigating DYNE-101 and DYNE-251, two therapies being developed by Dyne Therapeutics for the treatment of myotonic dystrophy and DMD.

Executed on:Mar 28, 2024 2:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Buffalo

Clinical Associate Professor of Neurology at the University of Buffalo.
Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.

Interview Goal

This call will discuss the current standard of care for myotonic dystrophy and duchenne muscular dystrophy. There will also be an analysis of the phase 1/2 ACHIEVE and DELIVER clinical trials on DYNE-101 and DYNE-251.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.